All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Results from a phase IIb, randomized, multicenter, placebo-controlled trial (NCT05153148) of zasocitinib (formerly TAK-279), a highly selective tyrosine kinase 2 (TYK2) inhibitor, were presented at the European Alliance of Associations for Rheumatology Congress 2024 by Alan Kivitz. Various doses of zasocitinib were investigated for efficacy and safety over 12 weeks in 290 patients with active psoriatic arthritis (PsA). The primary endpoint of the study was the proportion of patient achieving 20% improvement in the American College of Rheumatology score (ACR20) response at Week 12. We have previously reported results of zasocitinib in plaque psoriasis.
|
Key learnings: |
The safety profile of zasocitinib was consistent with previous studies, and no new safety signals were observed. |
The most common treatment-emergent adverse events in patients treated with zasocitinib were nasopharyngitis, upper respiratory tract infection, headache, and rash. |
At Week 12, a 20% improvement in the American College of Rheumatology score was seen in 35.2%, 53.3%, and 54.2% of patients treated with zasocitinib 5 mg, 15 mg, and 30 mg, respectively, compared with 29.2% of patients treated with placebo. Significantly more patients treated with 15 mg (p = 0.005) and 30 mg (p = 0.009) zasocitinib achieved the secondary endpoint of ACR50 vs placebo. |
With the lack of targeted oral therapies in PsA, zasocitinib is a promising emerging therapy in this patient population, with further studies in larger patient populations needed. |
Your opinion matters
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox